Caesarea, Israel (ots/PRNewswire) - Peer-Reviewed EuroIntervention Journal Publishes First-in-Human Study Finding Filterlex Medical's CAPTIS® Embolic Protection Device Performed Well and is Safe During Transcatheter Aortic Valve Replacement (TAVR). Filterlex Medical Ltd., a cardiovascular medical device startup, ...
Caesarea, Israel (ots/PRNewswire) - Cardiovascular data presented at EuroPCR 2022 demonstrates successful device performance during a TAVR procedure with no complications. Filterlex Medical Ltd., a cardiovascular medical device startup, announced today results from a first-in-human (FIH) study demonstrating the ...
Caesarea, Israel (ots/PRNewswire) - Cardiovascular study results to be presented by Prof. Ran Kornowski, Director of the Cardiology Center, Rabin Medical Center at the EuroPCR 2022 conference in May Filterlex Medical Ltd., a cardiovascular medical device startup, announced today that it has completed its CAPTIS ...
Caesarea, Israel (ots/PRNewswire) - Filterlex Medical, a cardiovascular medical device startup, announced today that it has been selected to receive €7 Million equity investment from the European Innovation Council Accelerator (EIC). The EIC equity investment will be a part of Filterlex's next round of financing. ...
Caesarea, Israel (ots/PRNewswire) - Filterlex Medical, a cardiovascular medical device startup, announced today that it has recently completed a US $6 Million series A1 investment round from leading private healthcare investors. The financing will accelerate implementation of the company's CAPTIS® clinical program. ...